Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
At the 2016 Annual Meeting of the European Society for Blood and Marrow Transplantation, held in Valencia, Spain, John Gribben, MD, from Barts Cancer Institute, London, UK, discusses how chronic lymphocytic leukemia (CLL) patients could soon benefit from specific treatments based on CLL characterization and their disease biology.
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.